Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Salvador Martin Algarra"'
Autor:
Phuong Tran, Shailender Bhatia, Agustin Vega-Crespo, Adi Diab, Gabriel Abril-Rodriguez, Walter J. Urba, Anusha Kalbasi, Katie M. Campbell, F. Stephen Hodi, Valsamo Anagnostou, Michael J. Quist, Cristina Puig-Saus, Craig L. Slingluff, Jennifer Tsoi, Petra Ross-Macdonald, Catherine S. Grasso, Jedd D. Wolchok, Antoni Ribas, John B. A. G. Haanen, Drew M. Pardoll, Egmidio Medina, Christophe Martignier, Yeon Joo Kim, Suzanne L. Topalian, Daniel Sanghoon Shin, Salvador Martin Algarra, Davis Y. Torrejon, Victor E. Velculescu, Ameya Champhekar, Bartosz Chmielowski, William H. Sharfman, Megan Wind-Rotolo, Jason J. Luke, Douglas B. Johnson, Mykola Onyshchenko, Daniel E. Speiser
Publikováno v:
Cancer cell, vol 38, iss 4
Cancer Cell
Cancer cell, vol 39, iss 1
Cancer Cell
Cancer cell, vol 39, iss 1
SUMMARY: We analyze the transcriptome of baseline and on-therapy tumor biopsies from 101 patients with advanced melanoma treated with nivolumab (anti-PD-1) alone or combined with ipilimumab (anti-CTLA-4). We find that T cell infiltration and interfer
Autor:
Caroline Robert, Richard F. Kefford, Jean-Jacques Grob, Axel Hauschild, Enrique Espinosa, Salvador Martin Algarra, Dirk Schadendorf, Piotr Rutkowski, Alexander M.M. Eggermont, Helen Gogas, Reinhard Dummer
The molecular classification of melanoma and the advent of new drugs are changing the paradigm of therapy for advanced melanoma. A review of the recent key studies was performed, followed by a discussion in an expert forum. The aim of this review was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a96f3d619d2431095cf9a737795be276
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84921435382
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84921435382
Autor:
Mariano Provencio Pulla, Joan Manel Gasent Blesa, Salvador Martin Algarra, Emilio González, Vicente Alberola Candel
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 11(1)
Platinum resistant ovarian cancer is a current challenge in Oncology. Current approved therapies offer no more of a 20% of response. New therapeutic options are urgently needed. Patients were treated with the combination of Pemetrexed 500 mg/m2 d1 an
Publikováno v:
Cancer metastasis reviews. 11(3-4)
Clinical trials of drugs that influence coagulation and fibrinolysis pathways have been undertaken in patients with malignancy because these pathways are capable of influencing malignant progression. The validity of this concept was originally confir